Advancing Myopia Management Will Unlock Global MedTech Potential

Key Takeaways

• Ongoing innovation in vision solutions and smart eyewear, along with strategic acquisitions, enhances competitive advantage and supports future market share and profitability.
  
• Global expansion, supply chain diversification, and direct-to-consumer initiatives drive top-line growth, operational resilience, and recurring revenue opportunities.
  
• Heavy investment in innovative eyewear and premium segments exposes EssilorLuxottica to technology, regulatory, economic, and margin risks amid intensifying competition and global cost pressures.

Catalysts

Designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, the Middle East, Africa, Europe, Latin America, and the Asia-Pacific.

• Strong pipeline of innovation in myopia management solutions (Stellest 2.0, DOT technology) and leadership in addressing rising vision disorders among children globally positions EssilorLuxottica to capture outsized growth from increasing myopia incidence, directly supporting future revenue and market share gains.
  
• Expanding global presence, especially in Asia and Latin America, leverages the growing middle class and improved healthcare access in emerging markets, opening new high-growth channels and supporting sustained top-line expansion.
  
• Investments in smart eyewear, AI-enabled vision solutions, and MedTech (Ray-Ban Meta, Oakley Meta, Nuance Audio, acquisition of Optegra Eye Clinics) capitalize on long-term demand for technologically advanced and personalized eye health platforms, catalyzing product mix upgrades and higher ASPs, which will benefit gross margin and future earnings.
  
• Ongoing vertical integration and supply chain diversification (new production facilities in France, Thailand, Laos, Mexico) improve operational efficiency and mitigate tariff/regulatory headwinds, preserving or expanding operating margins and providing resilience to exogenous shocks.
  
• Accelerating direct-to-consumer and subscription-based channels (notably in Europe and North America), plus deeper engagement with healthcare professionals, enable stronger customer acquisition, higher recurring revenues, and long-term margin improvement, supporting net income and cash flow growth.

EssilorLuxottica Société anonyme Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming EssilorLuxottica Société anonyme's revenue will grow by 6.2% annually over the next 3 years.
• Analysts assume that profit margins will increase from 8.7% today to 11.4% in 3 years time.
• Analysts expect earnings to reach €3.7 billion (and earnings per share of €7.91) by about July 2028, up from €2.4 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting €4.2 billion in earnings, and the most bearish expecting €3.0 billion.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 39.7x on those 2028 earnings, down from 50.0x today. This future PE is lower than the current PE for the GB Medical Equipment industry at 41.6x.
• Analysts expect the number of shares outstanding to grow by 0.15% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.89%, as per the Simply Wall St company report.

EssilorLuxottica Société anonyme Future Earnings Per Share Growth

Risks

• The rapid shift towards disruptive optical technologies, such as smart eyewear and AI-enabled glasses, carries substantial execution and adoption risks-if EssilorLuxottica is unable to maintain product relevance, successfully commercialize innovations, or keep pace with technology leaders, it could suffer from slower revenue growth and margin dilution, especially as wearables have been acknowledged as margin dilutive despite their sales momentum.
  
• Intensifying global tariff headwinds and persistent inflationary pressures (notably in the U.S. market) could erode gross margins and net income, with recent results already showing 80-90 basis points of margin dilution and management warning that mitigation strategies like price increases and supply chain relocation may only gradually offset these costs.
  
• The company's aggressive investment in MedTech and a growing assortment of premium/luxury segments (e.g., AI glasses, Stellest lenses, hearing aid eyewear) could make it increasingly vulnerable to economic downturns and cyclical spending contractions, thus exposing revenues and profitability to swings in discretionary consumer income and global macro risks.
  
• EssilorLuxottica's reliance on being the market leader in emerging medical and wearable categories heightens its exposure to tightening regulatory scrutiny and slow or fragmented reimbursement/approval processes (e.g., FDA approval for Stellest lenses), potentially delaying new revenue streams and pressuring earnings if regulatory hurdles or commercialization setbacks occur.
  
• The ongoing expansion of integrated, direct-to-consumer channels and major retail rollouts raises the risk of operational complexity and execution missteps, while at the same time global e-commerce and lower-cost competitors are driving greater price transparency and margin compression-pressuring EssilorLuxottica's long-term revenue growth and its ability to sustain premium pricing.

Valuation

• The analysts have a consensus price target of €261.167 for EssilorLuxottica Société anonyme based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €302.0, and the most bearish reporting a price target of just €180.0.
  
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be €32.7 billion, earnings will come to €3.7 billion, and it would be trading on a PE ratio of 39.7x, assuming you use a discount rate of 6.9%.
  
• Given the current share price of €258.3, the analyst price target of €261.17 is 1.1% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.